Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 3,767 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total value of $118,170.79. The sale was disclosed in a filing with the SEC, which is available at this link.

Gil M. Labrucherie also recently made the following trade(s):

  • On Tuesday, February 19th, Gil M. Labrucherie sold 3,592 shares of Nektar Therapeutics stock. The stock was sold at an average price of $42.39, for a total value of $152,264.88.

NKTR stock opened at $32.02 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $92.17. The firm has a market capitalization of $5.58 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The business had revenue of $28.22 million for the quarter, compared to analysts’ expectations of $25.45 million. During the same quarter in the previous year, the firm earned ($0.60) earnings per share. As a group, research analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of NKTR. Wellington Management Group LLP lifted its position in shares of Nektar Therapeutics by 20.7% during the 1st quarter. Wellington Management Group LLP now owns 12,961,558 shares of the biopharmaceutical company’s stock valued at $435,507,000 after buying an additional 2,220,193 shares during the last quarter. FMR LLC lifted its position in shares of Nektar Therapeutics by 8.5% during the 4th quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after buying an additional 2,041,954 shares during the last quarter. Norges Bank purchased a new position in shares of Nektar Therapeutics during the 4th quarter valued at $63,723,000. Vanguard Group Inc lifted its position in shares of Nektar Therapeutics by 3.6% during the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock valued at $1,153,525,000 after buying an additional 660,907 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Nektar Therapeutics by 131.6% during the 4th quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock valued at $31,125,000 after buying an additional 538,170 shares during the last quarter. 94.90% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have weighed in on NKTR. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. BidaskClub cut Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 18th. Svb Leerink began coverage on Nektar Therapeutics in a research report on Friday, March 15th. They issued a “mkt perform” rating and a $38.00 price objective on the stock. Finally, Leerink Swann began coverage on Nektar Therapeutics in a research report on Friday, March 15th. They issued a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. Nektar Therapeutics presently has an average rating of “Buy” and an average price target of $69.73.

TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) CFO Sells $118,170.79 in Stock” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2019/05/19/nektar-therapeutics-nktr-cfo-sells-118170-79-in-stock.html.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: Asset Allocation and Your Retirement

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.